A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients.

Bulletin du cancer

Volumn 91, Issue 12, 2004, Pages 279-284

  Louvet, C ^a   Andre T ^a   Gamelin, E ^a   Garcia, M L ^a   Saavedra, A ^a   Lenaers, G ^a   de Gramont, A ^a   Mery Mignard D ^a   Kalla, S ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; IRINOTECAN; PLEVITREXED; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COLON TUMOR; DRUG ADMINISTRATION; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTICENTER STUDY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RECTUM TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONIC NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEUTROPENIA; QUINAZOLINES; RECTAL NEOPLASMS;

EID: 13744262395     PISSN: None     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Article

References (0)